Clopidogrel Bisulfate
Product Images NDC 70934-797

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 70934-797). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Denton Pharma, Inc. Dba Northwind Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

70934 797 30 Master Bottle Label Approval Rev A 03 21

The text indicates the medicine is Clopidogrel, supplied in the form of tablets of 75mg strength containing 30 tablets in a pack. The NDC code printed on the packaging is 70934-797-30. The rest of the text is not legible and hence the description cannot be generated.*

FDA Label Image

Figure1 (Clopidogrel Fig)

FDA Label Image

Figure3 (Clopidogrel Fig2)

This is a chart or graph displaying the cumulative event rates of cardiovascular death, myocardial infarction, and stroke in patients who received either placebo (with aspirin) or clopidogrel (with aspirin) over the course of several months of follow-up. The graph shows that patients who received clopidogrel had significantly lower rates of these cardiovascular events compared to those who received only a placebo. It is noted that other standard therapies were also administered to the patients as necessary.*

FDA Label Image

Figure3 (Clopidogrel Fig3)

FDA Label Image

Figure4 (Clopidogrel Fig4)

The text describes a figure that shows the cumulative event rates for death in the COMMIT Study. The study compared the use of placebo and clopidogrel in treating patients with aspirin. The figure shows a 7% proportional risk reduction in death with clopidogrel compared to placebo, and this difference was statistically significant with a p-value of 0.03. The data is represented over a period of 28 days since randomization.*

FDA Label Image

Figure5 (Clopidogrel Fig5)

The text appears to be a comparison between Placebo and Clopidogrel. Both groups had a certain number of events, and a proportional risk of 9% was observed in favor of Clopidogrel. There was also a 7% reduction in death and a lower incidence of re-infarction or stroke before the first discharge. The data was evaluated up to 28 days since randomization.*

FDA Label Image

Figure6 (Clopidogrel Fig6)

FDA Label Image

Figure7 (Clopidogrel Fig7)

This appears to be a table or graph showing the cumulative event rates for fatal or non-fatal vascular events of two medications (Aspirin and Clopidogrel) over a 24-month follow-up period. The y-axis represents the percentage of cumulative event rate, while the x-axis shows the number of months of follow-up. However, without more information, it is difficult to provide a more specific description.*

FDA Label Image

Figure8 (Clopidogrel Fig8)

FDA Label Image

Structure (Clopidogrel Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.